Skip to main content
Clinical Trials/NCT05237778
NCT05237778CompletedNot Applicable

The Nightmare Catcher: Modulating Dreams With Targeted Memory Reactivation

University Hospital, Geneva2 sites in 1 country36 target enrollmentStarted: February 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
36
Locations
2
Primary Endpoint
Nightmare Frequency Questionnaire (NFQ)

Study Overview

Brief Summary

With this protocol, investigators examine whether targeted memory reactivation (TMR), a technique used to strengthen memories, can accelerate remission of nightmare disorder. This protocol uses TMR during REM sleep to strengthen positive memories generated by Imagery Rehearsal Therapy (IRT), a recommended treatment of nightmares. Patients with nightmare disorder are asked to perform an initial IRT session and, while they generate a positive outcome of their recurrent nightmare, half of the patients are exposed to a sound (TMR group), while no such pairing with a sound takes place for the other half (control group). During the next two weeks, all patients perform IRT every evening at home and are exposed to the sound during REM sleep with a wireless headband, which automatically detects sleep stages. Clinical evaluation of the severity of nightmares before and after (2-weeks follow-up and 3-months follow-up) this intervention takes place using the validated Nightmare Frequency Questionnaire (NFQ, primary outcome measure), which retrospectively identifies the frequency of nightmares. We hypothesize that patients treated with IRT and who are exposed, during REM sleep and over 14 nights, to a sound that had previously been associated with the new positive dream scenario of IRT (TMR group), will have more reduced frequency of nightmares compared to participants with stimulation of the same, but non-associated, sound during REM sleep (control group).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of nightmare disorder according to the International Classification of Sleep Disorders (ICSD-3) diagnostic and coding manual
  • Patients with at least moderate severity (>1 episode per week)

Exclusion Criteria

  • severe depression
  • insomnia disorder
  • psychosis or anxiety disorder
  • other sleep disorder (e.g.,obstructive sleep apnea syndrome, restless legs syndrome)
  • neurological disease
  • use of medications that would be likely to produce nightmares (e.g. hypnotics, β-blockers, amphetamines, antimicrobial agents)
  • use of anxiolytics, antipsychotic or antidepressant medication were excluded.

Outcomes

Primary Outcomes

Nightmare Frequency Questionnaire (NFQ)

Time Frame: 3 months

Validated self-report scale to assess the number of nightmares per week

Secondary Outcomes

  • Beck Depression Inventory (BDI-II)(3 months)
  • Nightmare Distress Questionnaire (NDQ)(3 months)
  • Pittsburgh Sleep Quality Index (PSQI)(3 months)
  • Proportion of the emotion 'fear' in dreams(2 weeks)
  • Proportion of the emotion 'joy' in dreams(2 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Lampros Perogamvros

Senior Clinical Fellow

University Hospital, Geneva

Study Sites (2)

Loading locations...

Similar Trials

Combined Treatment of Nightmares With... | Clinical Trial